Calamos Supports Greece

Donanemab

Second Alzheimer’s Drug to Slow Disease’s Progression

After Leqembi, another drug that might hit the market by the end of this year for Alzheimer's disease is Donanemab, and it's being developed by Eli Lilly. In a recent study, donanemab showed promise in slowing the progression of...

New Alzheimer’s Drug Slows the Disease by a Third

A new Alzheimer's drug called Donanemab has shown promising results in slowing down the disease's progression, which is caused by a sticky substance called beta-amyloid that builds up in the brain. Donanemab works similarly to another drug called Lecanemab,...